Drugs that contain Asciminib Hydrochloride

1. Drug name - SCEMBLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(10 years from now)

CN104302638B NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302638A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634B NOVARTIS For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives
May, 2033

(10 years from now)

EP2861576A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579B9 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861576B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.